Fig. 1

Percent of patients on clopidogrel at discharge and 6 months by CYP2C19 phenotype. PM poor metabolizer, IM intermediate metabolizer. Other includes normal metabolizers, rapid metabolizers, and ultra-rapid metabolizers. *p = 0.020 for PM versus other at 6 months. **p = 0.104 for IM versus other at 6 months